Tibsovo 250 mg film-coated tablets

DRUG6 trials

Sponsors

Technische Universitat Dresden, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Medizinische Hochschule Hannover, Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH, French Innovative Leukemia Organization

Conditions

Acute myeloid leukemiaAdult patients with relapsed or refractory IDH1-mutated AML or relapsed or refractory MDS/AMLAdvanced solid tumorMultiple myelomaNon-Hodgkin lymphomaPatients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutationT-cell prolymphocytic leukemiaacute myeloid leukemia (AML)

Phase 1

Phase Ia/IIb study of PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated relapsed/refractory AML or MDS/AML patients

RecruitingCTIS2024-514051-15-00

Medizinische Hochschule HannoverAdult patients with relapsed or refractory IDH1-mutated AML or relapsed or refractory MDS/AML, who are not eligible for intensive chemotherapy including alloHCT

Start: 2023-07-10Target: 27Updated: 2024-12-17

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation (alloSCT) In Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Neoplasia (HR-MDS) with IDH1 Mutation (PIVOT)

RecruitingCTIS2023-509055-14-00

Technische Universitat Dresdenacute myeloid leukemia (AML), myelodysplastic neoplasia (MDS)

Start: 2025-06-17Target: 76Updated: 2025-10-01

adIVO – A phase II trial of ivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

RecruitingCTIS2024-520219-42-00

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbHivosidenib maintenance after SOC adjuvant chemotherapy in curative mIDH1 cholangiocarcinoma

Start: 2025-11-18Target: 40Updated: 2025-11-18

FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

Not yet recruitingCTIS2025-521322-14-00

French Innovative Leukemia Organizationin complete remission after intensive chemotherapy., Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation

Target: 60Updated: 2025-11-17

A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy

Not yet recruitingCTIS2025-523238-17-00

Fundacion PETHEMAAcute myeloid leukemia

Target: 50Updated: 2026-02-19

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01